There are 2949 resources available
1370P - PD-L1 expression as a predictive biomarker for chemotherapy response in metastatic non-small cell lung cancer (mNSCLC)
Presenter: Rachel Woodford
Session: E-Poster Display
Resources:
Abstract
1371P - Randomized phase II trial of pemetrexed with or without bevacizumab maintenance after cisplatin, pemetrexed and bevacizumab in advanced non-squamous, non-small cell lung cancer (TORG1321)
Presenter: Tetsuro Kondo
Session: E-Poster Display
Resources:
Abstract
1372P - Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)
Presenter: Christian Grohé
Session: E-Poster Display
Resources:
Abstract
1373P - Difference in nephrotoxicity caused by cisplatin after a short or long hydration scheme in non-small cell lung cancer: A retrospective cohort study (HYCIS-XL)
Presenter: Kelly Niggebrugge-Mentink
Session: E-Poster Display
Resources:
Abstract
1374P - Docetaxel/nindetanib as efficient treatment option after failure of immune checkpoint inhibition: Real-world evidence
Presenter: Daniel C. Christoph
Session: E-Poster Display
Resources:
Abstract
1375P - Predicting chemotherapy toxicity in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan
Presenter: Motostugu Shimokawa
Session: E-Poster Display
Resources:
Abstract
1376P - Anlotinib combination with docetaxol for patients with previously treated advanced non-small cell lung cancer: A phase II, single-arm trial
Presenter: Xueqin Chen
Session: E-Poster Display
Resources:
Abstract
1377P - Exploratory analyses of efficacy from a phase III study comparing SB8, a proposed bevacizumab biosimilar, and reference bevacizumab in patients with metastatic or recurrent non-squamous NSCLC
Presenter: David Planchard
Session: E-Poster Display
Resources:
Abstract
1378P - Is 30-day mortality after systemic anticancer therapy in lung cancer in the era of varied treatments still relevant?
Presenter: Shefali Parikh
Session: E-Poster Display
Resources:
Abstract
1379P - Real-world (RW) clinical outcomes of patients with metastatic non-small cell lung cancer (mNSCLC) in the United Kingdom
Presenter: Jason Lester
Session: E-Poster Display
Resources:
Abstract